The haematological consequences of Plasmodium vivax malaria after chloroquine treatment with and without primaquine: a WorldWide Antimalarial Resistance Network systematic review and individual patient data meta-analysis
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“which is consistent with prior studies in Ethiopia as well as the findings of a systematic review of DHA/PPQ treatment for P. vivax [8, 40]”
In the citing paper
“A pooled analysis of clinical trials has shown that after the initial reduction in haemoglobin due to acute parasite or drug-related haemolysis, primaquine prevents further reductions in haemoglobin due to subsequent relapses and parasite-associated haemolysis [22].”
From Haematologic responses to primaquine used for radical cure of Plasmodium vivax in public health facilities in Ethiopia: a prospective observational study (2025) · cites this paper as [22]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Barnadas, C., Tichit, M., Bouchier, C., Ratsimbasoa, A., Randrianasolo, L., Raherinjafy, R., Jahevitra, M., Picot, S., & Ménard, D. (2008) · Malaria Journal · doi:10.1186/1475-2875-7-35 · Cited by 50
Research works printed but not linked: 56
- Tjitra E, Anstey NM, Sugiarto P, Warikar N, Kenangalem E, Karyana M, et al. Multidrug-resistant Plasmodium vivax associated with severe and fatal malaria: a prospective study in Papua. Indonesia PLoS Med. 2008;5(6):e128. · DOI · Paper page
- Genton B, D'Acremont V, Rare L, Baea K, Reeder JC, Alpers MP, et al. Plasmodium vivax and mixed infections are associated with severe malaria in children: a prospective cohort study from Papua New Guinea. PLoS Med. 2008;5(6):e127. · DOI · Paper page
- Price RN, Tjitra E, Guerra CA, Yeung S, White NJ, Anstey NM. Vivax malaria: neglected and not benign. Am J Trop Med Hyg. 2007;77(6 Suppl):79–87. · DOI · Paper page
- World Health Organization. World malaria report 2018. Geneva: World Health Organization; 2018. · DOI · Paper page
- Douglas NM, Anstey NM, Buffet PA, Poespoprodjo JR, Yeo TW, White NJ, et al. The anaemia of Plasmodium vivax malaria. Malar J. 2012;11:135. · DOI · Paper page
- Douglas NM, Lampah DA, Kenangalem E, Simpson JA, Poespoprodjo JR, Sugiarto P, et al. Major burden of severe anemia from non-falciparum malaria species in Southern Papua: a hospital-based surveillance study. PLoS Med. 2013;10(12):e1001575. · DOI · Paper page
- Price RN, Douglas NM, Anstey NM, von Seidlein L. Plasmodium vivax treatments: what are we looking for? Curr Opin Infect Dis. 2011;24(6):578–85. · DOI
- Tan KR, Hwang J. Tafenoquine receives regulatory approval in U.S. for prophylaxis of malaria and radical cure of Plasmodium vivax. J Travel Med. 2018:25(1). https://doi.org/10.1093/jtm/tay071 . · DOI
- von Seidlein L, Auburn S, Espino F, Shanks D, Cheng Q, McCarthy J, et al. Review of key knowledge gaps in glucose-6-phosphate dehydrogenase deficiency detection with regard to the safe clinical deployment of 8-aminoquinoline treatment regimens: a workshop report. Malar J. 2013;12:112. · DOI · Paper page
- Cappellini MD, Fiorelli G. Glucose-6-phosphate dehydrogenase deficiency. Lancet. 2008;371(9606):64–74. · DOI · Paper page
- Chu CS, Bancone G, Nosten F, White NJ, Luzzatto L. Primaquine-induced haemolysis in females heterozygous for G6PD deficiency. Malar J. 2018;17(1):101. · DOI · Paper page
- Thriemer K, Ley B, Bobogare A, Dysoley L, Alam MS, Pasaribu AP, et al. Challenges for achieving safe and effective radical cure of Plasmodium vivax: a round table discussion of the APMEN Vivax Working Group. Malar J. 2017;16(1):141. · DOI · Paper page
- World Health Organisation. Guidelines for the treatment of malaria - 3rd edition. Geneva: World Health Organization; 2015.
- Commons RJ, Thriemer K, Humphreys G, Suay I, Sibley CH, Guerin PJ, et al. The vivax surveyor: online mapping database for Plasmodium vivax clinical trials. Int J Parasitol Drugs Drug Resist. 2017;7(2):181–90. · DOI
- WorldWide Antimalarial Resistance Network. Data management and statistical analysis plan v1.2 Oxford: WorldWide Antimalarial Resistance Network; 2012 [Available from: www.wwarn.org/sites/default/files/ClinicalDMSAP.pdf .]
- Battle KE, Karhunen MS, Bhatt S, Gething PW, Howes RE, Golding N, et al. Geographical variation in Plasmodium vivax relapse. Malar J. 2014;13:144. · DOI · Paper page
- Lee SJ, Stepniewska K, Anstey N, Ashley E, Barnes K, Binh TQ, et al. The relationship between the haemoglobin concentration and the haematocrit in Plasmodium falciparum malaria. Malar J. 2008;7:149. · DOI
- WorldWide Antimalarial Resistance Network. Statistical analysis plan: WWARN Vivax Haematology Study Group v0.2 Oxford: WorldWide Antimalarial Resistance Network; 2016 [Available from: http://www.wwarn.org/sites/default/files/attachments/documents/wwarn_sap_haematology_290117.pdf .]
- Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics. 1982;38(4):963–74. · DOI · Paper page
- Royston P, Altman DG. Regression using fractional polynomials of continuous covariates: parsimonious parametric modelling (with discussion). J R Stat Soc. 1994;43:429–67.
- Royston P, Sauerbrei W. Multivariable model-building: a pragmatic approach to regression analysis based on fractional polynomials for modelling continuous variables. Chichester: Wiley; 2008. · DOI · Paper page
- Taylor WR, Widjaja H, Richie TL, Basri H, Ohrt C, Tjitra, et al. Chloroquine/doxycycline combination versus chloroquine alone, and doxycycline alone for the treatment of Plasmodium falciparum and Plasmodium vivax malaria in northeastern Irian Jaya, Indonesia. Am J Trop Med Hyg. 2001;64(5–6):223–228. · DOI
- Phan GT, de Vries PJ, Tran BQ, Le HQ, Nguyen NV, Nguyen TV, et al. Artemisinin or chloroquine for blood stage Plasmodium vivax malaria in Vietnam. Tropical Med Int Health. 2002;7(10):858–64. · DOI
- Leslie T, Mayan MI, Hasan MA, Safi MH, Klinkenberg E, Whitty CJ, et al. Sulfadoxine-pyrimethamine, chlorproguanil-dapsone, or chloroquine for the treatment of Plasmodium vivax malaria in Afghanistan and Pakistan: a randomized controlled trial. JAMA. 2007;297(20):2201–9. · doi:10.1001/jama.297.20.2201
- Ratcliff A, Siswantoro H, Kenangalem E, Wuwung M, Brockman A, Edstein MD, et al. Therapeutic response of multidrug-resistant Plasmodium falciparum and P. vivax to chloroquine and sulfadoxine-pyrimethamine in southern Papua, Indonesia. Trans R Soc Trop Med Hyg. 2007;101(4):351–9. · DOI · Paper page
- Leslie T, Mayan I, Mohammed N, Erasmus P, Kolaczinski J, Whitty CJ, et al. A randomised trial of an eight-week, once weekly primaquine regimen to prevent relapse of Plasmodium vivax in Northwest Frontier Province. Pakistan PLoS One. 2008;3(8):e2861. · DOI
- Ketema T, Bacha K, Birhanu T, Petros B. Chloroquine-resistant Plasmodium vivax malaria in Serbo town, Jimma zone, south-west Ethiopia. Malar J. 2009;8:177. · DOI
- Awab GR, Pukrittayakamee S, Imwong M, Dondorp AM, Woodrow CJ, Lee SJ, et al. Dihydroartemisinin-piperaquine versus chloroquine to treat vivax malaria in Afghanistan: an open randomized, non-inferiority, trial. Malar J. 2010;9:105. · DOI
- Phyo AP, Lwin KM, Price RN, Ashley EA, Russell B, Sriprawat K, et al. Dihydroartemisinin-piperaquine versus chloroquine in the treatment of Plasmodium vivax malaria in Thailand: a randomized controlled trial. Clin Infect Dis. 2011;53(10):977–84. · DOI · Paper page
- Poravuth Y, Socheat D, Rueangweerayut R, Uthaisin C, Pyae Phyo A, Valecha N, et al. Pyronaridine-artesunate versus chloroquine in patients with acute Plasmodium vivax malaria: a randomized, double-blind, non-inferiority trial. PLoS One. 2011;6(1):e14501. · DOI
- Barber BE, William T, Grigg MJ, Menon J, Auburn S, Marfurt J, et al. A prospective comparative study of knowlesi, falciparum, and vivax malaria in Sabah, Malaysia: high proportion with severe disease from Plasmodium knowlesi and Plasmodium vivax but no mortality with early referral and artesunate therapy. Clin Infect Dis. 2013;56(3):383–97. · DOI · Paper page
- Hwang J, Alemayehu BH, Reithinger R, Tekleyohannes SG, Takele T, Birhanu SG, et al. In vivo efficacy of artemether-lumefantrine and chloroquine against Plasmodium vivax: a randomized open label trial in central Ethiopia. PLoS One. 2013;8(5):e63433. · doi:10.1371/journal.pone.0063433
- Marques MM, Costa MR, Santana Filho FS, Vieira JL, Nascimento MT, Brasil LW, et al. Plasmodium vivax chloroquine resistance and anemia in the western Brazilian Amazon. Antimicrob Agents Chemother. 2014;58(1):342–7. · DOI
- Anez A, Moscoso M, Laguna A, Garnica C, Melgar V, Cuba M, et al. Resistance of infection by Plasmodium vivax to chloroquine in Bolivia. Malar J. 2015;14:261. · DOI
- Getachew S, Thriemer K, Auburn S, Abera A, Gadisa E, Aseffa A, et al. Chloroquine efficacy for Plasmodium vivax malaria treatment in southern Ethiopia. Malar J. 2015;14:525. · DOI · Paper page
- Gomes Mdo S, Vieira JL, Machado RL, Nacher M, Stefani A, Musset L, et al. Efficacy in the treatment of malaria by Plasmodium vivax in Oiapoque, Brazil, on the border with French Guiana: the importance of control over external factors. Malar J. 2015;14:402. · doi:10.1186/s12936-015-0925-7
- Lidia K, Dwiprahasto I, Kristin E. Therapeutic effects of dyhidroartemisinin piperaquine versus chloroquine for uncomplicated vivax malaria in Kupang, East Nusa Tenggara, Indonesia. Int J Pharm Sci Rev Res. 2015;31(2):247–51.
- Rishikesh K, Kamath A, Hande MH, Vidyasagar S, Acharya RV, Acharya V, et al. Therapeutic assessment of chloroquine-primaquine combined regimen in adult cohort of Plasmodium vivax malaria from a tertiary care hospital in southwestern India. Malar J. 2015;14:310. · DOI
- Thanh PV, Hong NV, Van NV, Louisa M, Baird K, Xa NX, et al. Confirmed Plasmodium vivax resistance to chloroquine in central Vietnam. Antimicrob Agents Chemother. 2015;59(12):7411–9. · DOI
- Grigg MJ, William T, Menon J, Barber BE, Wilkes CS, Rajahram GS, et al. Efficacy of artesunate-mefloquine for chloroquine-resistant Plasmodium vivax malaria in Malaysia: an open-label, randomized, controlled trial. Clin Infect Dis. 2016;62(11):1403–11. · DOI
- Ley B, Alam MS, Thriemer K, Hossain MS, Kibria MG, Auburn S, et al. G6PD deficiency and antimalarial efficacy for uncomplicated malaria in Bangladesh: a prospective observational study. PLoS One. 2016;11(4):e0154015. · DOI
- Pereira D, Daher A, Zanini G, Maia I, Fonseca L, Pitta L, et al. Safety, efficacy and pharmacokinetic evaluations of a new coated chloroquine tablet in a single-arm open-label non-comparative trial in Brazil: a step towards a user-friendly malaria vivax treatment. Malar J. 2016;15:477. · DOI
- Saravu K, Kumar R, Ashok H, Kundapura P, Kamath V, Kamath A, et al. Therapeutic assessment of chloroquine-primaquine combined regimen in adult cohort of Plasmodium vivax malaria from primary care centres in southwestern India. PLoS One. 2016;11(6):e0157666. · DOI · Paper page
- Thuan PD, Ca NT, Van Toi P, Nhien NT, Thanh NV, Anh ND, et al. A randomized comparison of chloroquine versus dihydroartemisinin-piperaquine for the treatment of Plasmodium vivax infection in Vietnam. Am J Trop Med Hyg. 2016;94(4):879–85. · doi:10.4269/ajtmh.15-0740
- Wangchuk S, Drukpa T, Penjor K, Peldon T, Dorjey Y, Dorji K, et al. Where chloroquine still works: the genetic make-up and susceptibility of Plasmodium vivax to chloroquine plus primaquine in Bhutan. Malar J. 2016;15(1):277. · DOI
- Abreha T, Hwang J, Thriemer K, Tadesse Y, Girma S, Melaku Z, et al. Comparison of artemether-lumefantrine and chloroquine with and without primaquine for the treatment of Plasmodium vivax infection in Ethiopia: a randomized controlled trial. PLoS Med. 2017;14(5):e1002299. · DOI · Paper page
- Siqueira AM, Alencar AC, Melo GC, Magalhaes BL, Machado K, Alencar Filho AC, et al. Fixed-dose artesunate-amodiaquine combination vs chloroquine for treatment of uncomplicated blood stage P. vivax infection in the Brazilian Amazon: an open-label randomized, controlled trial. Clin Infect Dis. 2017;64(2):166–74. · DOI
- Chu CS, Phyo AP, Lwin KM, Win HH, San T, Aung AA, et al. Comparison of the cumulative efficacy and safety of chloroquine, artesunate, and chloroquine-primaquine in Plasmodium vivax malaria. Clin Infect Dis. 2018;67(10):1543-9. · DOI · Paper page
- Grigg MJ, William T, Barber BE, Rajahram GS, Menon J, Schimann E, et al. Age-related clinical spectrum of Plasmodium knowlesi malaria and predictors of severity. Clin Infect Dis. 2018;67(3):350–9. · DOI
- Chu CS, Phyo AP, Turner C, Win HH, Poe NP, Yotyingaphiram W, et al. Chloroquine versus dihydroartemisinin-piperaquine with standard high-dose primaquine given either for 7 days or 14 days in Plasmodium vivax malaria. Clin Infect Dis. 2019:68(8):1311-9. · DOI
- Pukrittayakamee S, Vanijanonta S, Chantra A, Clemens R, White NJ. Blood stage antimalarial efficacy of primaquine in Plasmodium vivax malaria. J Infect Dis. 1994;169(4):932–5. · DOI
- Commons RJ, Simpson JA, Thriemer K, Humphreys GS, Abreha T, Alemu SG, et al. The effect of chloroquine dose and primaquine on Plasmodium vivax recurrence: a WorldWide Antimalarial Resistance Network systematic review and individual patient pooled meta-analysis. Lancet Infect Dis. 2018;18(9):1025-34. · DOI · Paper page
- Luxemburger C, van Vugt M, Jonathan S, McGready R, Looareesuwan S, White NJ, et al. Treatment of vivax malaria on the western border of Thailand. Trans R Soc Trop Med Hyg. 1999;93(4):433–8. · DOI
- Llanos-Cuentas A, Lacerda MV, Rueangweerayut R, Krudsood S, Gupta SK, Kochar SK, et al. Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study. Lancet. 2014;383(9922):1049–58. · DOI · Paper page
- Chu CS, Bancone G, Moore KA, Win HH, Thitipanawan N, Po C, et al. Haemolysis in G6PD heterozygous females treated with primaquine for Plasmodium vivax malaria: a nested cohort in a trial of radical curative regimens. PLoS Med. 2017;14(2):e1002224. · DOI · Paper page
- Plewes K, Kingston HWF, Ghose A, Maude RJ, Herdman MT, Leopold SJ, et al. Cell-free hemoglobin mediated oxidative stress is associated with acute kidney injury and renal replacement therapy in severe falciparum malaria: an observational study. BMC Infect Dis. 2017;17(1):313. · DOI
Cited by
Assefa, A., Mohammed, H., Anand, A., Abera, A., Sime, H., Minta, A. A., Tadesse, M., Tadesse, Y., Girma, S., Bekele, W., et al. (2022) · Malaria Journal · doi:10.1186/s12936-022-04350-z · Cited by 20
Self-citationShifraw, T., Abdelmenan, S., Zewde, A., Worku, A., Abera, A., Mohammed, H., Etana, K., Keating, J., Chibsa, S., Girma, S., et al. (2025) · Malaria Journal · doi:10.1186/s12936-025-05709-8
Self-citation
Metadata
- Authors
- Commons, R. J., Simpson, J. A., Thriemer, K., Chu, C. S., Douglas, N. M., Abreha, T., Alemu, S. G., Añez, A., Anstey, N. M., Aseffa, A., Assefa, A., Awab, G. R., Baird, J. K., Barber, B. E., Borghini-Fuhrer, I., D’Alessandro, U., Dahal, P., Daher, A., de Vries, P. J., Erhart, A., Gomes, M. S. M., Grigg, M. J., Hwang, J., Kager, P. A., Ketema, T., Khan, W. A., Lacerda, M. V. G., Leslie, T., Ley, B., Lidia, K., Monteiro, W. M., Pereira, D. B., Phan, G. T., Phyo, A. P., Rowland, M., Saravu, K., Sibley, C. H., Siqueira, A. M., Stepniewska, K., Taylor, W. R. J., Thwaites, G., Tran, B. Q., Hien, T. T., Vieira, J. L. F., Wangchuk, S., Watson, J., William, T., Woodrow, C. J., Nosten, F., Guerin, P. J., White, N. J., & Price, R. N.
- Venue
- BMC Medicine
- Published
- 2019-08-01
- Volume
- 17
- Issue
- 1
- ISSN
- 1741-7015
- Cited by
- 51
- References
- 1
- Language
- en
- Licence
- creativecommons.org/licenses/by/4.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor)
- Funders
- National Health and Medical Research Council (1104975, 1135820, 1138860, 1134989)
- Royal Australasian College of Physicians
- Bill and Melinda Gates Foundation (OPP1164105 and OPP1054404)
- Wellcome Trust (200909)
- Asia Pacific Malaria Elimination Network (None)
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
- Tropical Network Fund, Nuffield Department of Clinical Medicine, University of Oxford (None)
- Exxon Mobil Corporation (None)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The haematological consequences of Plasmodium vivax malaria after chloroquine treatment with and without primaquine: a WorldWide Antimalarial Resistance Network systematic review and individual patient data meta-analysis. https://app.cochat.ai/papers/10.1186/s12916-019-1386-6
- The paper
- Commons, R. J., Simpson, J. A., Thriemer, K., Chu, C. S., Douglas, N. M., Abreha, T., Alemu, S. G., Añez, A., Anstey, N. M., Aseffa, A., Assefa, A., Awab, G. R., Baird, J. K., Barber, B. E., Borghini-Fuhrer, I., D’Alessandro, U., Dahal, P., Daher, A., de Vries, P. J., . . . Price, R. N. (2019). The haematological consequences of Plasmodium vivax malaria after chloroquine treatment with and without primaquine: a WorldWide Antimalarial Resistance Network systematic review and individual patient data meta-analysis. BMC Medicine. https://doi.org/10.1186/s12916-019-1386-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.